Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback

Bone Marrow Transplantation

Volumn 32, Issue 1, 2003, Pages 23-30

  Chakrabarti, S ^a   Brown, J ^a   Guttridge, M ^b   Pamphilon, D H ^a,b   Lankester, A ^b   Marks, D I ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

CD34+selection; Lymphocyte recovery; T cell addback

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GANCICLOVIR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MALE; MORTALITY; PERIPHERAL BLOOD STEM CELL; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD3; ANTIGENS, CD34; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOCYTE TRANSFUSION; LYMPHOPOIESIS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; PROBABILITY; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0037480046     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704082     Document Type: Review

References (42)

1. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
2. Popplewell LL, Forman SJ. Is there an upper age limit for bone marrow transplantation. Bone Marrow Transplant 2002; 29: 277-284.
3. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
4. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231-1237.
5. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-767.
6. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
7. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
8. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
9. Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083-1090.
10. Marks DI, Bird JM, Vettenranta K et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2000; 6: 646-653.
11. Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
12. Chakrabarti S, MacDonald D, Hale G et al. T cell depletion with campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003; 121: 109-118.
13. Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 9: 467-480.
14. Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341-1347.
15. Martinez C, Urbano-Ispizua A, Rozman C et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999; 27: 561-568.
16. Watts MJ, Somervaille TC, Ings SJ et al. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. Br J Haematol 2002; 118: 117-123.
17. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
18. Chakraverty R, Robinson S, Peggs K et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 827-834.
19. Sutherland R, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34 enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. J Hematother 1996; 3: 213-226.
20. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
21. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
22. Schattenberg A, Schaap N, Preijers F et al. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. Bone Marrow Transplant 2000; 26: 17-22.
23. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770-773.
24. Bornhauser M, Platzbecker U, Theuser C et al. CD34+ -enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte addback. Br J Haematol 2002; 118: 1095-1103.
25. Pavletic ZS, Joshi SS, Pirruccello SJ et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33-41.
26. Einsele H, Ehninger G, Steidle M et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672-1678.
27. Chakrabarti S, Mautner V, Osman H et al. Adenovirus infections following allogeneic stem cell transplantation: the incidence and outcome in relation to graft manipulation, immunosuppression and immune recovery. Blood 2002; 100: 1619-1627.
28. Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001; 72: 1460-1463.
29. Storek J, Gooley T, Witherspoon RP et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997; 54, 131-138.
30. Powles R, Singhal S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481-3486.
31. Kumar S, Chen MG, Gastineau DA et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001; 28: 951-956.
32. Bunjes D, Hertenstein B, Wiesneth M et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant 1995; 15: 563-568.
33. Martino R, Caballero MD, Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-2245.
34. Brunet S, Urbano-Ispizua A, Ojeda E et al. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114: 544-550.
35. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
36. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
37. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98: 2900-2908.
38. Urbano-Ispizua A, Rozman C, Pimentel P et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002; 100: 724-727.
39. Urbano-Ispizua A, Rozman C, Pimentel P et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
40. Rebello P, Cwynarsky K, Varughese M et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy 2002; 3: 261-267.
41. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of CMV infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
42. Chakrabarti S, Fegan C, Milligan DW. Campath-1H in the bag for T cell depletion in allogeneic peripheral blood stem cell transplantation from related and unrelated donors reduces both acute and chronic GVHD and limits transplant-related mortality. Bone Marrow Transplant 2002; 28 (Suppl. 2): 446.